Vanderbilt-Ingram Cancer Center

Click a box below to view trial details

Acute Myeloid Leukemia

Correlative

VICC HEM 1305
Investigating abnormal signaling in acute myeloid leukemia (AML)

Registry

VICC HEM 14133
Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Untreated

VICC HEM 1073
The Role of the Native Immune System in Determining Outcome Following AML Induction Therapy
*For patients on standard of care or clinical trial regimens

IDH1 and/or IDH2 mutation

VICC HEM 15113
A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation

Patients Age < 30

COG AAML 1031
AAML1031 - A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ ITD

Intermediate to high risk ≥ 18 years old (allows good risk if patient is not a candidate for anthra-cyclines)

*1st priority over E1203 and E2906

VICC HEM 1553
Phase II Trial of Vosaroxin in Combination with Infusional Cytarabine in Patients with Untreated AML

Patients Age ≥ 60

ECOG HEM E2906
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age greater than or less than 60 Years)

Patients > 65 who are not eligible for standard anthracy-cline based induction therapy

VICC HEM 14132
A Phase 1/2 Study of ABT199 in Combination with LowDose Cytarabine in TreatmentNaïve Subjects with Acute Myeloge nous Leukemia Who Are ≥ 65 Years of Age and Who Are Not Eligible for Standard Anthracycline Based Induction Therapy

VICC HEM 1656
A Randomized, Multicenter, Open-Label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination with Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 Years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)